Angela Shen

10.4k total citations · 2 hit papers
37 papers, 6.3k citations indexed

About

Angela Shen is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Angela Shen has authored 37 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Molecular Biology and 8 papers in Genetics. Recurrent topics in Angela Shen's work include CAR-T cell therapy research (15 papers), Lymphoma Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Angela Shen is often cited by papers focused on CAR-T cell therapy research (15 papers), Lymphoma Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Angela Shen collaborates with scholars based in United States, Malaysia and Spain. Angela Shen's co-authors include Bruce L. Levine, Carl H. June, Stephan A. Grupp, Simon F. Lacey, Anne Chew, Noelle V. Frey, J. Joseph Melenhorst, Pamela A. Shaw, Zhaohui Zheng and Vanessa Gonzalez and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Angela Shen

36 papers receiving 6.2k citations

Hit Papers

Chimeric Antigen Receptor T Cells for Sustained Remission... 2014 2026 2018 2022 2014 2015 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
    2014 3.9k citations Shannon L. Maude, Noelle V. Frey et al. New England Journal of Medicine profile →
  2. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
    2015 1.3k citations Wei‐Ting Hwang, Noelle V. Frey et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angela Shen United States 18 5.2k 1.8k 1.8k 1.4k 1.4k 37 6.3k
Vanessa Gonzalez United States 8 5.0k 1.0× 1.5k 0.8× 1.8k 1.0× 1.5k 1.0× 1.4k 1.0× 20 5.6k
Nabil Ahmed United States 27 4.1k 0.8× 1.3k 0.7× 1.8k 1.0× 1.1k 0.8× 1.4k 1.0× 90 5.7k
Laïla‐Aïcha Hanafi United States 16 3.3k 0.6× 1.3k 0.7× 1.1k 0.6× 919 0.6× 1.0k 0.7× 24 4.3k
Irina Marić United States 35 3.4k 0.7× 1.7k 1.0× 2.3k 1.3× 945 0.7× 699 0.5× 126 6.3k
Dean A. Lee United States 51 5.7k 1.1× 2.3k 1.3× 5.2k 2.9× 1.4k 1.0× 966 0.7× 248 8.7k
Bianca Santomasso United States 19 3.2k 0.6× 779 0.4× 764 0.4× 683 0.5× 653 0.5× 46 3.7k
Julie R. Ostberg United States 30 3.3k 0.6× 1.4k 0.8× 1.9k 1.0× 1.1k 0.8× 1.4k 1.0× 43 4.8k
Anita Schmitt Germany 33 1.7k 0.3× 1.0k 0.6× 1.6k 0.9× 441 0.3× 239 0.2× 142 3.5k
Sudhakar Tummala United States 21 2.3k 0.4× 503 0.3× 523 0.3× 386 0.3× 523 0.4× 73 3.2k
Tiejuan Mi United States 26 1.5k 0.3× 1.4k 0.8× 1.1k 0.6× 545 0.4× 470 0.3× 39 3.8k

Countries citing papers authored by Angela Shen

Since Specialization
Citations

This map shows the geographic impact of Angela Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Shen more than expected).

Fields of papers citing papers by Angela Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Shen. The network helps show where Angela Shen may publish in the future.

Co-authorship network of co-authors of Angela Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Shen. A scholar is included among the top collaborators of Angela Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Shen. Angela Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Miller, Samara, Daniele Marcotulli, Angela Shen, & Larry S. Zweifel. (2019). Divergent medial amygdala projections regulate approach–avoidance conflict behavior. Nature Neuroscience. 22(4). 565–575. 84 indexed citations
3.
Scott, Luisa L., James J. Sahn, Antonio Ferragud, et al.. (2018). Small molecule modulators of σ2R/Tmem97 reduce alcohol withdrawal-induced behaviors. Neuropsychopharmacology. 43(9). 1867–1875. 32 indexed citations
4.
Zierath, Dannielle, et al.. (2018). Chemical Sympathectomy, but not Adrenergic Blockade, Improves Stroke Outcome. Journal of Stroke and Cerebrovascular Diseases. 27(11). 3177–3186. 3 indexed citations
5.
Sun, Baohua, Warren Fiskus, Yimin Qian, et al.. (2017). BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 32(2). 343–352. 136 indexed citations
6.
Zierath, Dannielle, et al.. (2017). Splenectomy Does Not Improve Long-Term Outcome After Stroke. Stroke. 48(2). 497–500. 23 indexed citations
7.
Rosen, Lee S., Patricia LoRusso, Wen Wee, et al.. (2016). A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Investigational New Drugs. 34(5). 604–613. 62 indexed citations
8.
O’Rourke, Donald M., MacLean P. Nasrallah, Jennifer D. Morrissette, et al.. (2016). Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. Cancer Research. 76(14_Supplement). LB–83. 3 indexed citations
9.
10.
Porter, David L., Simon F. Lacey, Wei‐Ting Hwang, et al.. (2014). Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. Blood. 124(21). 1983–1983. 6 indexed citations
11.
Maude, Shannon L., Noelle V. Frey, Pamela A. Shaw, et al.. (2014). Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New England Journal of Medicine. 371(16). 1507–1517. 3933 indexed citations breakdown →
12.
Frey, Noelle V., Bruce L. Levine, Simon F. Lacey, et al.. (2014). Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells. Blood. 124(21). 2296–2296. 30 indexed citations
13.
14.
Rosen, Lee S., Patricia LoRusso, Wen Wee, et al.. (2011). Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. Cancer Research. 71(8_Supplement). 4716–4716. 18 indexed citations
15.
Wu, Joseph T., S. K. Edward, Daniel K. W. Chu, et al.. (2011). A serial cross-sectional serologic survey of 2009 Pandemic (H1N1) in Hong Kong: implications for future pandemic influenza surveillance.. PubMed. 5(Suppl 1). 190–4. 4 indexed citations
16.
Radford, John, Andrew Davies, Martin J.S. Dyer, et al.. (2010). Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. British Journal of Haematology. 149. 2–3. 1 indexed citations
17.
Wu, Joseph T., S. K. Edward, Cheuk Kwong Lee, et al.. (2010). The Infection Attack Rate and Severity of 2009 Pandemic H1N1 Influenza in Hong Kong. Clinical Infectious Diseases. 51(10). 1184–1191. 148 indexed citations
18.
Sureda, Anna, Anas Younes, Dina Ben‐Yehuda, et al.. (2010). Final Analysis: Phase II Study of Oral Panobinostat In Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant. Blood. 116(21). 419–419. 23 indexed citations
19.
Schwartz, Gary K., et al.. (2009). A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3513–3513. 78 indexed citations
20.
Rubenstein, James L., Angela Shen, Lauren E. Abrey, et al.. (2004). Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 22(14_suppl). 6593–6593. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vanessa Gonzalez Breakdown of academic impact, for papers by Nabil Ahmed Breakdown of academic impact, for papers by Laïla‐Aïcha Hanafi Breakdown of academic impact, for papers by Irina Marić Breakdown of academic impact, for papers by Dean A. Lee Breakdown of academic impact, for papers by Bianca Santomasso Breakdown of academic impact, for papers by Julie R. Ostberg Breakdown of academic impact, for papers by Anita Schmitt Breakdown of academic impact, for papers by Sudhakar Tummala Breakdown of academic impact, for papers by Tiejuan Mi
Rankless by CCL
2026